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Abstract
 
The prelude to type-1 diabetes is leukocyte infiltration into the pancreatic islets, or insulitis.
This process begins in pancreatic lymph nodes when T lymphocytes reactive to islet 
 
 
 
 cells
encounter antigen-presenting cells (APCs) displaying peptides derived from 
 
 
 
 cell proteins.
We show here that a ripple of physiological 
 
 
 
 cell death, which occurs at 2 wk of age in all
mouse strains, precipitates the arrival of such APCs, and that the relevant APC is a dendritic
cell of CD11c
 
 
 
CD11b
 
 
 
CD8
 
 
 
 
 
 phenotype. These findings have significant implications con-
cerning the nature of the diabetes-provoking deficits in NOD mice, the identity of the primordial
diabetogenic antigens, and our understanding of the balance between immunity and tolerance
in a pathological context.
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Introduction
 
In type-I diabetes, the insulin-producing 
 
 
 
 cells of the pan-
creatic islets of Langherhans are destroyed by T lymphocyte–
provoked mechanisms (1). During the first stage of this
biphasic autoimmune disease, termed insulitis, the islets are
invaded by a mix of leukocytes, including DCs, macro-
phages, B cells, and CD4
 
 
 
 and CD8
 
 
 
 T cells. After a relatively
benign interlude, the islet infiltrate converts to a pathological
lesion, resulting in the eventual destruction of a majority of
the 
 
 
 
 cells. The ensuing loss of glucose homeostasis leads to
a series of debilitating disorders collectively known as diabetes.
In immune responses in general, naive T cells are activated
by DCs in peripheral lymphoid organs (2). Because circu-
lating naive T cells cannot usually access peripheral non-
lymphoid tissues, the tissue-derived antigens they recognize
must be transported to T cell zones of nearby lymphoid
organs and processed into MHC–peptide complexes.
Upon antigen recognition and activation, the T cells prolif-
erate and differentiate into effector cells, which circulate
through nonlymphoid tissues and are retained where they
rerecognize cognate antigen.
The autoimmune response that results in 
 
 
 
 cell destruction
follows the same basic scheme, with 
 
 
 
 cell–specific T cells
being primed in pancreatic LNs (PLNs) and activated T
cells invading the islets shortly thereafter (3, 4). In the
BDC2.5 TCR transgenic (tg) mouse model of autoimmune
diabetes (derived from a diabetogenic, 
 
 
 
 cell–reactive,
CD4
 
 
 
 T cell clone; references 5, 6), the priming of poten-
tially diabetogenic CD4
 
 
 
 T cells is subject to temporal reg-
ulation, commencing with striking synchronicity from 15
to 18 d of age (3). Analogous observations have been made
in at least three other TCR tg models in which CD4
 
 
 
 or
CD8
 
 
 
 T cells, specific for 
 
 
 
 cell epitopes presented by H-2
 
b
 
,
H-2
 
d
 
, or H-2
 
g7
 
 molecules, are first sensitized in PLNs at
 
 
 
15 d of age (3, 7–9). Together, these observations argue
that the temporal control of islet-specific T cell priming is
not restricted to a particular TCR tg system, applies to
both MHC class I– and class II–restricted 
 
 
 
 cell–specific T
cells, and is not a unique property of the NOD genetic
background.
The lack of autoreactive T cell priming in the PLNs of
day 10 mice suggests that one of the following players in
the autoimmune response is either absent or functionally
impaired at this time: the antigen, the T cell, or the APC.
A deficiency in antigen expression cannot account for this
phenomenon because relevant 
 
 
 
 cell antigens are expressed
in neonates (7, 8, 10), and their expression levels do not
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greatly increase between 10 and 20 d of age (reference 7;
unpublished data). A functional incompetence of 
 
 
 
 cell–
reactive T cells in 10-d-old mice has also been ruled out by
transfer experiments (3). This suggests that changes in
APCs underlie the initiation of autoantigen exposure be-
cause of altered ability to pick up, process, transport, or
present pancreatic antigens, or because the relevant 
 
 
 
 cell
antigens are not made available to them for some reason.
Here, we explore alterations in APC function and 
 
 
 
 cell
death as possible triggers for activation of diabetogenic T
cells in the PLN.
 
Materials and Methods
 
Mice. 
 
The generation and maintenance of BDC2.5/NOD
and BDC2.5/B6.H2
 
g7/g7
 
 TCR tg mice were described previously
(5, 11). The BDC2.5 TCR recognizes a 
 
 
 
 cell peptide associated
with I-A
 
g7
 
. For typing of BDC2.5 mice, monoclonal antibodies
directed against CD4 and V
 
 
 
4 were used. Caspase-12 knockout
mice were obtained from J. Yuan (Harvard Medical School, Bos-
ton, MA) on the C57/Bl6 background and were crossed to con-
genic C57Bl/6.H2
 
g7/g7
 
 or NOD backgrounds. All mice were
maintained under barrier conditions in the Joslin Diabetes Center
Animal Facility.
 
Flow Cytometric Analysis of DCs. 
 
LN and pancreatic cell sus-
pensions were prepared as described previously (12). Organs
were teased and digested in Ca
 
2
 
 
 
-free buffer containing Collage-
nase P or D (Roche Molecular Biochemicals) at 37
 
 
 
C for 20
min. Digested material was pipetted vigorously and filtered in
cold wash buffer containing 5–10 mM EDTA. Cells were
washed, and erythrocytes were lysed in pancreatic suspensions
using NH
 
4
 
Cl. After blocking with purified 
 
 
 
-Fc
 
 
 
R (2.4G2),
bulk organ suspensions were stained for multicolor flow cytome-
try in PBS/2% FCS using cocktails of monoclonal antibodies.
Antibodies specific for MHC class II (10-3.6), CD40 (3/23),
CD54 (3E2), CD80 (16-10A1), CD11c (HL3), and CD4 (L3T4)
were purchased from BD Biosciences. Antibodies specific for
B220 (CD45R), CD11b (M1/70), and CD8
 
 
 
 (CT-CD8
 
 
 
) were
purchased from Caltag. Directly conjugated isotype controls in-
cluded mouse IgG
 
2a
 
, rat IgG
 
2a
 
, and Armenian hamster IgG (BD
Biosciences). For dead cell exclusion, suspensions were incu-
bated with Hoescht 33342 (HO; Calbiochem) for 5 min on ice
before analysis, and dead cells, which stain brightly with HO,
were detected with the UV laser. Cell suspensions were prepared
rapidly and analyzed immediately to avoid maturation and/or
fixation artifacts. Dead cells (HO
 
hi
 
) and B220
 
hi
 
 cells were ex-
cluded during analysis. For DC analysis, samples were acquired
with a MoFlo (DakoCytomation) and analyzed using the Sum-
mit software.
 
Analysis of Antigen Transport. 
 
Mice were anesthetized and
their abdomens were opened to access the pancreas for injection.
Pancreata were injected with fluorescein-conjugated ovalbumin
(Fluo.Ova) (500 
 
 
 
g/adult, 250 
 
 
 
g/juvenile; Molecular Probes),
0.5 
 
 
 
m YG carboxylate polystyrene microspheres (0.25% solid;
Polysciences, Inc.), or CFSE-labeled adult NOD hepatocytes
(10
 
6
 
/adult, 0.5 
 
 
 
 10
 
6
 
/juvenile). Hepatocytes were prepared by
digesting teased livers in collagenase-containing buffer at 37
 
 
 
C for
10 min. Liver suspensions were depleted of erythrocytes using
NH
 
4
 
Cl and washed hepatocytes were resuspended in warm PBS/
0.1% BSA. CFSE-labeling was performed as described previously
(3). Cells were washed and resuspended in PBS. Before injection,
 
 
 
90% hepatocytes stained positively with trypan blue.
 
Endocytosis Assay. 
 
PLN cell suspensions were prepared from
NOD mice using collagenase to extract DCs from tissues (as de-
scribed in the 
 
Flow Cytomeric Analysis of DCs
 
 section). Cells were
incubated at 37 or 4
 
 
 
C in RPMI 1640 complete medium (5%
FCS) without antigen or with graded doses of Fluo.Ova for 30
min. Cells were washed three times in cold medium and stained
with antibodies specific for CD11c and MHC class II on ice for
cytofluorimetry. The fraction of Fluo.Ova
 
 
 
 cells and the mean
fluorescence intensity of Fluo.Ova were determined.
 
Assessment of T Cell Activation. 
 
T cell activation was assessed
using an adoptive transfer system with CFSE-labeled lymphocytes
as described previously (3). Draining (PLNs) and nondraining LNs
(inguinal lymph nodes [ILNs]) were harvested 
 
 
 
66 h after transfer
and single cell suspensions were prepared using glass slide disrup-
tion. Bulk LN cells were stained with 
 
 
 
-CD4 or 
 
 
 
-V
 
 
 
4 and
 
 
 
-CD44 for flow cytometric measurement of T cell activation.
The extent of T cell proliferation was determined simultaneously
by CFSE dilution analysis. For T cell analysis, samples were ac-
quired using Coulter instrumentation and analyzed with Expo
software. T cells were transferred 24–48 h after administration of
drugs or antigen. We observed high levels of CD44 expression on
all BDC2.5 T cells (gated on transferred cells as follows: CD4
 
 
 
CFSE
 
 
 
 or V
 
 
 
4
 
 
 
CFSE
 
 
 
) diluting CFSE in PLNs. For dying islet
cell injections, pancreatic islets of Langerhans were isolated from
4–6-wk-old NOD mice at the Joslin Diabetes Center Islet Core,
resuspended in PBS, and subjected to four cycles of freezing and
thawing to induce 100% necrosis in samples. Each recipient mouse
received the equivalent of 100 islets intrapancreatically.
 
Drugs. 
 
Streptozotocin (STZ; Sigma-Aldrich) was resus-
pended in sodium citrate buffer immediately before intraperito-
neal injection and administered 1
 
 
 
 at 80 mg/kg. Benzyloxylcar-
bonyl-V-A-
 
d
 
-
 
O
 
-methyl fluoromethyl ketone (ZVAD; Calbiochem)
was dissolved in DMSO and injected intraperitoneally. Each mouse
received 100 
 
 
 
l of a 10 
 
 
 
M ZVAD solution.
 
Immunizations. 
 
NOD mice were anesthetized, and a single
hind footpad was injected with 10 
 
 
 
g of the mimic peptide, 1040-
63 (Peptron; reference 13), 24 h after ZVAD administration.
 
Results
 
DCs in PLNs from 10- versus 20-d-old Mice.
 
Given that
DCs transport tissue antigens to LNs and activate cognate
T cells encountered there, it is reasonable to speculate that
the absence of T cell priming in PLNs of 10-d-old mice
and its presence in PLNs of 20-d-old mice may reflect al-
terations in local DC representation or function. To inves-
tigate this possibility, we compared the composition of
DC subsets in days 10 and 20 PLNs from NOD mice us-
ing multicolor cytofluorimetry. Single cell suspensions
were analyzed without preenrichment to prevent any loss
of potentially important cells; instead, they were stained
with appropriate reagents for excluding dead cells and
lymphocytes. Using a combination of classical DC mark-
ers, we identified four subsets of myeloid cells in day 20
PLNs, distinguished by surface expression of CD11c and/
or CD11b (Fig. 1, top left) as follows: subset 1,
CD11b
 
 
 
CD11c
 
 
 
; subset 2, CD11b
 
2
 
 
 
CD11c
 
 
 
; subset 3,
CD11b
 
 
 
CD11c
 
   
 
; and subset 4, CD11b
 
 
 
CD11c
 
2
 
 
 
.
Subset 1 is partially comprised of F4/80
 
 
 
 macrophages
(unpublished data). To characterize DC populations of the
PLN-expressing lymphoid markers, we stained suspensionsT
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with Abs specific for CD8
 
 
 
 and CD4 in combination with
the DC markers CD11c and CD11b. Distinct CD8
 
 
 
 
 
CD11c
 
 
 
 DCs (Fig. 1, subset 5, bottom left) lacking
CD11b expression (not depicted) were identified. PLN
DCs lacking CD8
 
 
 
 were subdivided into CD11c
 
lo
 
CD8
 
 
 
 
 
(subset 6) and CD11c
 
hi
 
CD8
 
 
 
 
 
 (subset 7) subsets (Fig. 1,
bottom left). A population of CD4
 
 
 
 DCs (CD4
 
 
 
CD11c
 
   
 
CD11b
 
 
 
) was also detected within subset 3 of
day 20 PLNs (unpublished data).
We characterized the makeup of day 10 PLNs, and
found DC subsets 1–7 to be readily detectable (Fig. 1,
right). In addition, no significant differences were mea-
sured in the relative abundances (expressed as percentage of
total myeloid cells) of subsets 1–7 between days 10 and 20
PLNs (Fig. 1, table). PLNs were also sampled before day
10 (as early as day 4) and between days 11 and 19; in all
cases, the relative levels of subsets 1–7 were essentially
identical to those found in 10- and 20-d old (unpublished
data). Therefore, these results indicate that the major PLN
DC subsets are all present from shortly after birth and do
not substantially change in relative abundance between
days 4 and 20. The absolute cellularity of all DC subsets in-
creased approximately threefold between days 10 and 20,
whereas the absolute cellularity of the total PLN aug-
mented approximately fivefold during this period (d10
 
PLN 
 
  
 
3 
 
  105 cells; day 20   1.5   106 cells). Thus,
DCs comprise an increasingly smaller proportion of the to-
tal PLN as this organ develops.
To investigate the possibility that islet-specific T cell
priming does not occur in PLNs of 10-d-old animals be-
cause of ineffective DC maturation, we examined the sur-
face expression of classical DC maturation markers by each
of the subsets described in Fig. 1. As shown for subsets 1–4
in Fig. 2, the expression profiles of CD40, CD54, CD80,
CD86, and MHC class II molecules on subsets 1, 3, and 4
were not markedly different between days 10 and 20. Data
for subsets 5–7 prompted a similar conclusion (unpublished
data). However, MHC class II and CD86 molecules were
consistently up-regulated between days 10 and 20 by DCs
belonging to subset 2 (CD11b2 CD11c ).
Transport of Pancreatic Antigens to PLNs in 10- and 20-d-old
NOD Mice. Pancreatic antigens must be shuttled to the
PLNs and presented to circulating naive T cells to initiate
insulitis. Because little is known of antigen transit from
the pancreas to the draining LN, we sought to examine
this pathway in some detail. First, we established a method
Figure 1. Composition of PLN DCs at days 10 (d10) and 20 (d20).
DC subsets in PLNs of 10- and 20-d-old NOD mice were stained with
CD11c (x axis) and CD11b or CD8  (y axis). Dotplots (gated on
B220 HO ) are representative of results from  15 experiments. Values
in table indicate the proportion of each subset expressed as the percentage
of total myeloid (CD11b CD11c ) cells (average   SD of three inde-
pendent experiments).
Figure 2. Expression of maturation markers by PLN DCs at days 10
(d10) and 20 (d20). Surface expression of MHC class II, CD40, CD54,
CD80, and CD86 molecules compared on subsets 1–4 described in Fig. 1
from PLNs of 10- and 20-d-old NOD mice. Isotype controls are shown
for each subset. Value in top right corner of each histogram indicates
mean fluorescence intensity of specified marker. Histograms represent results
of 4–10 experiments.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Autoantigen Release to Dendritic Cells after   Cell Apoptosis 1530
for monitoring specific antigens as they accumulated in
the PLNs after drainage from the pancreas; cytofluorime-
try was used to quantitatively assess transport of various
forms of antigens to the PLNs after direct injection into
the adult pancreas.
Injection of Fluo.Ova into the pancreas resulted in its
detection in a clear number of PLN CD11c  DCs (Fig. 3).
The extent was maximal  20 h after administration (un-
published data), a time course reminiscent of similar studies
of antigen transport after airway exposure (14). This en-
couraged the use of a similar approach to examine transport
of antigens more relevant to diabetes, specifically two par-
ticulate antigens that may mimic fragments of dying   cells
as follows: (a) fluorescently labeled hepatocytes (Fluo.Cells)
and (b) fluorescently labeled microspheres (Fluo.Beads).
We used primary hepatocytes as surrogate   cells because
the latter are difficult to obtain in sufficient numbers for
detection in a cytofluorimetry-based migration assay. Try-
pan-positive hepatocytes, generated by collagenase treat-
ment of liver, were labeled with CFSE and injected
directly into the pancreas. The transport kinetics of
Fluo.Cells and Fluo.Beads, monitored by cytofluorimetry,
differed from those of soluble antigen, taking  40 h for
optimal detection in the PLNs. The majority of APCs
bearing Fluo.Ova and Fluo.Cells were CD11c , whereas
the APCs containing Fluo.Beads were both CD11c  and
CD11c  (Fig. 3 a). We also examined the relative abun-
dances and absolute numbers of DCs in the PLNs after in-
trapancreatic injection of antigen (Fig. 3 b). The numbers
of PLN DCs do not significantly change after administra-
tion of Fluo.Ova, Fluo.Cells, or Fluo.Beads.
To discern whether soluble antigen (Fluo.Ova) was ac-
quired by DCs in the PLNs or at the site of antigen appli-
cation, we followed an approach described in a study of
airway antigen transport (14). As in the lung study, we
found that Fluo.Ova could be detected in CD11cint
MHCIIhi DCs  20 h after intrapancreatic injection of the
soluble antigen but not in CD11chiMHCIIlo DCs (Fig. 3 c,
top). We tested the ability of these two populations to
capture Fluo.Ova ex vivo and found that their endo-
cytic capacities were nearly identical (Fig. 3 c, bottom). If
Fluo.Ova was getting to the PLNs by passive leakage, we
would have expected to see this antigen associated with
both of the PLN DC populations because they both avidly
endocytose Fluo.Ova upon deliberate exposure. Because
was associated with CD11cintMHCIIhi DCs but not CD11chiMHCIIlo
DCs in vivo. The line graphs depict the in vitro endocytic capacity of
CD11chiMHCIIlo (open squares) and CD11cintMHCIIhi (closed squares)
DC populations. The fraction of Fluo.Ova  cells within and the amount
of antigen captured by each DC population were similar. (d) Phenotypic
characterization of antigen-bearing (Fluo ) cells in 4-wk-old NOD
PLNs. The leftmost panel represents total PLN cells (no Fluo or FL1
gate) after a mock intrapancreatic injection. The other dotplots display
antigen-bearing (Fluo ) cells in PLNs after intrapancreatic injection of
specified antigen. Values in dotplots depict the percentage of antigen-
bearing cells (Fluo ) within the individual gates. Data are representative
of four to six experiments.
Figure 3. Transport of pancreatic antigens to draining LNs. (a) Flow
cytometric assessment of antigen transport to PLN after intrapancreatic
injection of PBS, Fluo.Ova, Fluo.Cells, or Fluo.Beads into  20-d-old
NOD mice. Antigen-bearing cells (Fluo ) are plotted versus CD11c 
cells. PLNs were harvested  20 h after Fluo.Ova administration and
 40 h after administration of Fluo.Cells or Fluo.Beads. Value shown in
top right corner of the dotplots is the percentage of antigen-bearing cells
(Fluo ) among CD11c  cells. (b) Quantification of DCs in 4-wk-old
PLNs before and after administration of Fluo.Ova, Fluo.Cells, and
Fluo.Beads. The relative abundance (left) and absolute number (right) of
DCs (CD11c  cells) per PLN are shown. (c) Characterization of antigen
capture by distinct DC subsets in vivo and in vitro. Cell suspensions from
PLNs were stained with CD11c (y axis) and MHC class II (x axis). Left
contour plot depicts total DCs in the PLNs, whereas right contour plot
depicts Fluo.Ova  DCs in PLN after intrapancreatic injection. Fluo.OvaT
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this was clearly not the case, we concluded that Fluo.Ova 
PLN DCs captured their antigen in the pancreas and mi-
grated to the draining LNs rather than capturing their anti-
gen within the LNs.
Next, we pinpointed the specific DC subsets mediating
  cell–derived antigen transport in 20-d-old mice.
Fluo.Ova and Fluo.Cells were detected largely in CD11c 
DCs, whereas Fluo.Beads were seen in both CD11b 
macrophages and CD11b  DCs (Fig. 3 d, top row).
Soluble  protein (Fluo.Ova) and particulate antigens
(Fluo.Cells, Fluo.Beads) were associated with both
CD8   and CD8   DCs (Fig. 3 d, bottom row); how-
ever, the CD8   DCs played a more minor role than
CD8   DCs. All three of the antigens tested were absent
from the CD4 CD11b  DC population corresponding to
subset 3 delineated in the first paragraph of Results (un-
published data).
Having established that fragments of dying cells are
transported from the pancreas to the PLNs by DCs in day
20 mice, we asked whether the initiation of insulitis might
be controlled by a developmental change in the ability of
DCs to capture and transport dying cells. To test this, we
injected Fluo.Cells into pancreata of 8- and 20-d-old recip-
ients and monitored Fluo.Cell-trafficking to PLNs  42 h
later. As in 20-d-old, CD11c  DCs, primarily CD8  ,
were largely responsible for ferrying Fluo.Cells to the PLNs
in 10-d-old (Fig. 4, left). The frequency of CD11b  DCs
transporting Fluo.Cells increased from 21 to 40% between
days 10 and 20. These data demonstrate that pancreatic
Figure 4. Antigen transport by day 10 (d10) pancreatic DCs. Flow
cytometric analysis of antigen-bearing cells (Fluo ) in  10- and 20-d-old
NOD mice 40 h after intrapancreatic injection of Fluo.Cells into NOD
mice. Total PLN cells are shown in the left column and antigen-bearing
(Fluo ) cells in the right column for both ages. The values in top right
corner of dot plot indicate the percentage of Fluo  DCs expressing
CD11b (top plots) or CD8  (bottom plots) in gate above dotted line.
Data are representative of two to four experiments.
Figure 5. The presence of dead   cells provokes
activation of naive BDC2.5 T cells in neonatal PLNs.
(a) Activation of transferred naive BDC2.5 T cells
(gated on CD4 V 4  cells) in PLNs and ILNs after intra-
pancreatic implantation of dead islets or buffer into
6-d-old NOD mice. Proliferation was assessed in all
experiments  66 h after transfer by CFSE dilution in
CD4  T cells. (b) Activation of transferred naive
BDC2.5 T cells (gated on CD4 V 4  cells) in PLNs
after intraperitoneal injection of STZ into 6-d-old
NOD mice.T
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DCs are indeed equipped to capture and transport dying
cells to PLNs by 10 d of age.
A Role for   Cell Death in Triggering Diabetogenic T
Cells. A potential trigger for initiation of the antiislet re-
sponse that culminates in diabetes development might be
  cell death (for review see reference 15). In addition to
the steady-state   cell turnover known to occur through-
out life (16), it has been reported that rodents (and hu-
mans) exhibit a transient ripple of   cell death shortly after
birth, thought to be a normal physiological process reflect-
ing tissue remodeling or metabolic perturbations (17–21).
In mice, this occurs at  12 d of age, only a brief time be-
fore the window of initial priming of naive, potentially di-
abetogenic T cells in the PLNs. Thus, it is tempting to
speculate that the increase in   cell death at 12 d of age
augments capture, transport, and presentation of   cell an-
tigens by DCs, leading to antiislet T cell activation from
15 to 18 d of age.
We tested this notion with different strategies using the
BDC2.5 TCR tg system. The still-unidentified antigen
recognized by BDC2.5 T cells appears to be associated
with particulate fractions of   cells, possibly on the cyto-
plasmic face of secretory granules (22). Although the
BDC2.5 antigen is known to be synthesized shortly after
birth (10), its subcellular localization suggests that it might
be more likely encountered when the integrity of the   cell
membrane is disrupted, for example, during programmed
cell death or cell injury. To assess this possibility, we trans-
ferred CFSE-labeled naive BDC2.5 T cells into 6-d-old
NOD mice that were unmanipulated or had been intrapan-
creatically implanted with dead islets. The activation of
these transferred cells and their proliferation in draining and
distal LNs was ascertained by flow cytometry 66 h after
transfer, as a dilution of the CFSE label with each cell divi-
sion. In the latter case, a much higher fraction (47 vs. 3%)
of the transferred T cells was activated and proliferated in
the PLNs, a clear response to dying   cells (Fig. 5 a). The
intrapancreatic injection of buffer alone resulted in a small
increase in BDC2.5 T cell activation (3 vs. 13%) in PLNs,
suggesting that the surgical procedure may have caused
some   cell death (Fig. 5 a). Transferred BDC2.5 T cells
remained naive in ILNs in all recipients (Fig. 5 a). We also
transferred CFSE-labeled naive BDC2.5 T cells into 6-d-old
recipients that had or had not been treated with STZ, a
Figure 6.   cell death is required for
optimum BDC2.5 T cell priming. (a)
Effect of systemic ZVAD treatment on
naive BDC2.5 T cell activation in PLNs
of 14–42-d-old NOD mice. The left
histograms depict BDC2.5 T cell prolif-
eration, assessed by CFSE dilution in
CD4 V 4  cells, in the PLNs of 21–
42-d-old mice after ZVAD treatment
(administered at day 2). BDC2.5 T cell
activation was impaired by 40% on aver-
age (P    0.0001). The histograms in
right column display T cell proliferation
in popliteal LNs of ZVAD-treated
NOD mice after footpad immunization
with BDC2.5 peptide mimic. BDC2.5
T cells do not proliferate in popliteal
LNs of unimmunized recipients (shaded
histogram). Bar graph depicts BDC2.5
T cell proliferation in the PLNs or ILNs
of 14-d-old after ZVAD treatment at
day 2. (b) BDC2.5 T cell activation in
PLNs of caspase-12–deficient B6.H2g7/g7
mice (KO) and wild-type littermate
controls (WT). Proliferation of trans-
ferred naive BDC2.5 T cells, assessed by
CFSE dilution in CD4 V 4  cells, was
reduced by 56% on average in KO re-
cipients (P    0.006). Graph on right
shows the proliferation indices for naive
wild-type BDC2.5 T cells after transfer
into 17–25-d-old caspase-12 KO mice
or wild-type littermates on the B6.H2g7/g7
background. Each symbol represents an
individual mouse.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Turley et al. 1533
cytotoxic drug to which   cells are particularly sensitive. A
single injection of STZ resulted in a much more robust
PLN activation (64 vs. 2%) of the transferred T cells (Fig. 5
b). These results indicate that   cell death within the pan-
creas is capable of provoking priming of islet-reactive
CD4  T cells circulating through PLNs before 10 d of age.
If experimental induction of   cell death could promote
activation of   cell–reactive T cells circulating through the
PLNs of perinatal mice, might physiological   cell death be
a trigger for the antiislet reactivity that initiates insulitis and
eventually culminates in diabetes? To address this question,
we treated mice with the irreversible pancaspase inhibitor,
ZVAD, to block caspase-dependent   cell death in situ,
and examined priming of transferred BDC2.5 T cells in the
PLNs. NOD mice received a single injection of ZVAD at a
dose shown previously to inhibit liver abscess formation in
a mouse model of parasite infection (23). To ascertain that
this systemic ZVAD treatment was effectively blocking cas-
pase activity, we examined the effects in the thymus, be-
cause apoptosis associated with thymocyte selection is
readily detectable in this tissue. Using cytofluorimetry, we
found that a single dose of ZVAD inhibited death of dou-
ble-negative thymocytes in vivo by 50% (unpublished
data), suggesting that the drug was having an effect, though
one that was probably only partial. To minimize any po-
tential effects of ZVAD on donor T cells, we administered
the inhibitor 24–48 h before transfer of T cells. A single in-
jection of ZVAD into 21–42-d-old recipients before T cell
transfer impaired activation of naive BDC2.5 T cells by
40% on average (P   0.0001; Fig. 6 a, left histograms).
Treatment of 12-d-old mice with ZVAD impaired the ac-
tivation of naive BDC2.5 T cells by 50% (Fig. 6 a, bar
graph). Systemic ZVAD treatment did not alter resident
APCs or transferred T cell function because no significant
difference was observed in T cell activation in popliteal
LNs of ZVAD-treated and untreated animals that had been
immunized with a mimotope recognized by BDC2.5 T
cells (Fig. 6 a, right histograms; reference 13). Therefore,
spontaneous priming of BDC2.5 T cells in the PLNs of
young mice is controlled, at least in part, by caspase-medi-
ated apoptosis of   cells.
Because pancreatic   cells seem particularly prone to
death in response to protein overexpression (24), we specu-
lated that the physiological   cell death in young mice
might be mediated by caspase-12, a death-promoting en-
zyme specifically activated by ER stress (25). Therefore, we
backcrossed the caspase-12 knockout mutation (25) onto
the NOD and B6.H2g7 backgrounds, intercrossed, and
transferred naive, CFSE-labeled, BDC2.5 T cells into cas-
pase-12–deficient mice and control littermates. Lack of cas-
pase-12–impaired T cell proliferation in 17–25-d-old mice
by 56% on average (P   0.006; Fig. 6 b). These results sug-
gest that the caspase-12–dependent ER stress pathway of  
cell death may control, at least partially, the availability of  
cell–derived antigens in the PLNs.
NOD and Other Strains. On the one hand, it has been
reported that NOD mice show defective clearance of ap-
optotic cells by macrophages (26). On the other hand, it
was shown that the time of insulitis onset was the same for
BDC2.5 TCR tgs on the NOD and B6.H-2g7 genetic
backgrounds (6). Therefore, we wondered how the release
and transport of   cell antigens to the PLNs and the activa-
tion of islet-reactive T cells compared in these two strains.
We found that the ability to activate transferred naive
BDC2.5 T cells occurred with essentially superimposable
kinetics in the PLNs of NOD or B6.H2g7 recipients, with a
transition past 15 d of age in both strains (Fig. 7 a). There-
fore, developmental regulation of anti–  cell T cell prim-
ing is not a unique fate of autoimmuneprone NOD mice.
As with NOD mice again, we found that inhibition of
apoptosis in young B6.H2g7 mice lead to a marked reduc-
tion (50%) in the activation of transferred naive BDC2.5 T
cells in the PLN (Fig. 7 b). Thus, priming of potentially di-
abetogenic T cells is governed by a physiological process
common to multiple mouse strains, and does not reflect
NOD-specific aberrations in APCs or   cells.
Discussion
Two New Features. Results from several previous stud-
ies have converged to suggest the following scenario of in-
Figure 7. Regulation of autoreactive T cell priming not determined by
NOD background. (a) Naive BDC2.5 T cell activation was assessed in
PLNs of NOD and B6.H2g7/g7 mice at different ages ranging from 7 to 28 d
of age. CFSE dilution in BDC2.5 T cells (gated on CD4 V 4  cells) was
measured in all recipients  66 h after transfer. (b) Effect of systemic
ZVAD treatment on naive BDC2.5 T cell activation (measured by CFSE
dilution in CD4 V 4  cells) in PLNs of 21-d-old B6.H2g7/g7 recipients.
Systemic ZVAD treatment caused a 50% decrease in proliferation of
BDC2.5 T cells in PLNs of B6.H2g7/g7 mice.T
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sulitis initiation in the NOD mouse model of type-1 diabe-
tes (and its TCR tg derivatives). Like all antigen-ignorant
lymphocytes, naive   cell–reactive T cells circulate through
the blood and lymphoid tissues of juvenile mice. Through
some process beginning at  2 wk of age, antigens derived
from   cells are taken up by APCs in the pancreatic islets,
inducing their migration to the immediately draining LNs,
the PLNs, and their maturation en route. In the PLNs, the
APCs present   cell–derived antigens to naive   cell–reac-
tive T cells in circulation and activate them. Upon activa-
tion, the T cells acquire the ability to migrate through the
tissues; in the islets, they reencounter cognate antigen, be-
come reactivated, and are retained, thereby initiating insu-
litis (for review see reference 15). Findings from the present
set of experiments elucidate this scenario by revealing two
important new features.
First, the stimulus initiating insulitis appears to be a ripple
of   cell death that occurs physiologically in juvenile mice
of all strains. The abrupt onset of islet infiltration in
BDC2.5 TCR tg animals from 15 to 18 d of age reflects the
acquisition of a new competence by APCs in the PLNs to
present   cell–derived antigens to circulating   cell–reac-
tive T cells (3). Incompetence before this time could reflect
a deficiency in the APCs and/or the antigens. We show
here that PLN APCs from juvenile mice are of standard
composition (Figs. 1 and 2) and that, within days after birth,
APCs are fully capable of taking up antigen in the pancreas
(Figs. 3–5) and offering it to CD4  T cells in the PLN (Fig.
5). This finding is consistent with previous works indicat-
ing that the machinery for presentation of MHC class
I–restricted peptides to CD8  T cells in the PLNs (7, 9)
and spleen (27) of neonatal mice is intact. Clearly, the rele-
vant APCs are there and are functional in juvenile mice.
Likewise, we have shown previously that the   cell–
derived antigen recognized by BDC2.5 T cells is present
within days after birth (reference 10; unpublished data).
However, it remained possible that, although synthesized,
the antigen is not made available for presentation until the
abrupt occurrence of some event at  2 wk of age.
An intriguing possibility was that an augmentation of  
cell death that occurs in the islets around this time is the
precipitating event, a normal physiological process termed
“tissue remodeling.” Several groups have reported such an
increase in rodents, peaking  12 d after birth (17–20). Sig-
nificant   cell death at this age was first surmised from
mathematical modeling studies (17); confirmation came
from quantifying dying cells on pancreas sections (18, 19).
The frequency of defunct cells was low even at peak times
(4–13%), but, given that they can be very difficult to detect
(owing to rapid engulfment and disposal), it is possible that
a significant fraction (estimated at one third) of the   cells
in juvenile rodents is turning over at this time. Interest-
ingly, an analogous perinatal wave of   cell death, peaking
at birth, has been demonstrated in the islets of humans,
leading to the suggestion that extension of this wave might
be the cause of hyperinsulinemia in infancy (21). Because
dead cells can be a potent activation signal for APCs, in
particular DCs, this ripple of   cell death could provide a
trigger for mobilization of potentially diabetogenic T cells.
Our studies provide both “gain of function” and “loss of
function” arguments in favor of this notion. On the one
hand, extraneously introducing dead   cells into the pan-
creas (Fig. 5 a) or provoking death specifically of   cells in
vivo via injection of STZ (Fig. 5 b) prematurely precipi-
tated the appearance of the BDC2.5 antigen on the surface
of PLN APCs as early as 6 d of age. These results are in line
with previous conclusions that experimental induction of  
cell death via CTLs (7) or STZ (9) promoted activation of
naive CD8    cell–specific T cells in the PLNs of neonatal
mice, and that STZ treatment exacerbated insulitis in adult
mice by enhancing the priming of T cells responsive to  
cell antigens (28). These results argue that induction of  
cell death can lead to the priming of naive diabetogenic T
cells, but stops short of demonstrating that it actually does
so during spontaneous disease development. On the other
hand, inhibiting caspase-dependent cell death either by
treatment of mice with ZVAD (Fig. 6 a) or by using a cas-
pase-12–deficient mouse line (Fig. 6 b) delayed the arrival
of BDC2.5–antigen-loaded APCs in the PLNs of juvenile
mice. However, neither pharmacological nor genetic inhi-
bition of caspase activity was able to halt progression to in-
sulitis or diabetes; indeed, in both cases, inhibition of the
PLN activation of transferred BDC2.5 T cells was only
partial. The incomplete effects of ZVAD in halting
BDC2.5 T cell priming were not very surprising given that
systemic administration of this drug did not completely
block cell death (reference 23; unpublished data), even
when the drug was continuously infused into the target tis-
sue (29). The incomplete effects of the caspase-12 defi-
ciency also have ample precedent; drug-induced, ER
stress-mediated apoptosis of diverse cell-types was far from
totally inhibited in the knock-out mice (25). The partiality
of both types of caspase inhibition may indicate that addi-
tional caspases or other death signaling molecules are in-
volved in these processes, or at least can be mobilized in a
state of deficiency. It is known, for example, that the death
of some cell types can change from an apoptotic to a ne-
crotic mechanism by depleting ATP or blocking the activ-
ity of caspases. Most relevant here is that, although tran-
siently inhibiting cell death in several contexts, ZVAD did
not promote a long-term increase in cell viability (30–33).
The second important feature revealed by the present
studies is that the APC that ferries   cell debris from the
pancreas to the PLNs is a DC of CD11b CD8   pheno-
type. Although it has been known for some time that DCs
express a wide array of receptors for internalizing diverse
ligands (34), the uptake of dying cells by DCs originally
came as somewhat of a surprise because macrophages were
thought to be the specialists in clearing cellular debris at
that time (35). Several analyses subsequently demonstrated
that cell-associated antigens could be captured, processed,
and presented by splenic DCs (36, 37). Tissue-restricted
antigens have been detected in DCs within regional lym-
phatics and tissue-draining LNs (38, 39); however, the spe-T
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cific mechanisms by which DCs encounter and transport
parenchymal cell antigens has remained unclear.
We examined the transport of dying parenchymal cells
from the pancreas to the PLNs, and found that CD11c 
DCs were pivotal in this process (Fig. 3 a), both CD11b 
and CD11b  DCs being involved (Fig. 3 b). Interestingly,
the relative abundance of CD11b  DCs carrying dying cell
fragments to the PLNs augmented between days 10 and 20,
and these cells up-regulated expression of MHC class II
molecules and CD86 during the same time window. Simi-
larly, we observed a mobilization of CD11b  DCs from
the pancreas into the PLNs in response to STZ-induced  
cell death (unpublished data). These results are of interest in
light of a recent paper that CD11b  DCs were more effi-
cient than CD11b  DCs at activating an islet-specific T cell
hybridoma after induction of a limited amount of   cell
death in vivo (28). Fragments of endogenous dead cells
have been detected in both CD8   and CD8   DCs, al-
though engulfment of intravenously administered cells was
attributed to the CD8   subset of spleen DCs (37, 40). In
contrast, we found that CD8   DCs contributed only
minimally to the transport of dying cells from the pancreas
to the PLNs (Fig. 4). This is supported by our observation
that DCs residing in the pancreas, where antigen is initially
encountered, were largely CD11b CD8   as follows: 60%
of pancreatic DCs expressed CD11b; and 96% lacked
CD8  expression (unpublished data). Likewise, stomach
DCs that captured parietal cell antigens expressed CD11b
but not CD8  (39). These discrepancies might be due to
tissue-specific differences in DC subsets or to differences in
the nature of the engulfed dying cell. However, in general,
it seems that our findings on the pancreas–PLN axis are
very reminiscent of what occurs with stomach antigens.
Implications. This new information may have some
profound implications for how insulitis is initiated in pre-
lude to type-1 diabetes. One of the more important impli-
cations relates to the factors responsible for the predisposi-
tion of NOD mice to spontaneously develop diabetes. A
ripple of physiological   cell death occurs at  2 wk of age
in the islets of all mouse strains examined thus far, includ-
ing B6 (20). This may be somewhat more pronounced in
NOD mice (20), which might reflect a reported deficit in
the phagocytosis of apoptotic cells by macrophages derived
from these animals (26). However, any such differences
seem not to read out further downstream. Results pre-
sented in Fig. 7 and as described previously (6) argue that
caspase-dependent release of   cell–derived antigens to the
PLNs and spontaneous initiation of islet invasion by a  
cell–reactive T cell clone, respectively, are indistinguishable
on the B6.H-2g7 and NOD genetic backgrounds. It would
appear most likely that NOD mice are diabetes-prone not
because of an aberrant self stimulation but rather of an ab-
normal self response; i.e., they have an autoreactive T lym-
phocyte repertoire insufficiently purged of cells capable of
responding to   cell antigens. This interpretation is sup-
ported by recent claims of defects in the negative selection
of NOD thymocytes (41, 42).
Another important implication of our findings concerns
the antigens responsible for triggering type-1 diabetes.
There has been much debate on this topic, with a primary
role being assigned to insulin, glutamic acid decarboxylase,
heat shock protein, or a variety of other proteins (43, 44).
The indiscriminate release of   cell antigens implied in a
scenario rooted in physiological cell death could explain
why it has been so difficult to convincingly identify the
primordial diabetogen. If the ripple of   cell death that oc-
curs in the islets of juvenile mice is indeed translated into
an influx into the PLNs of DCs displaying   cell–derived
antigens, and assuming that a multitude of proteins is re-
leased from dying cells, then multiple   cell antigens
should be simultaneously presented after this event (45).
The coordinated priming of T cells with reactivities to di-
verse   cell proteins (BDC2.5, OT-I, clone-4, 8.3) at  15
d of age suggests that this is in fact the case (3, 7–9). This
conclusion may seem at odds with older works about a
temporal sequence to the priming of   cell–reactive T
cells of different specificities (46, 47), but this hierarchy
could conceivably reflect differing sensitivities of the assays
used to read out the responses. Release of antigens to the
PLNs by a normal physiological process also eliminates the
need to invoke molecular mimicry by microbial T cell
epitopes to initiate the autoimmune process, as done, for
example, by Mintern et al. (7). This notion has attracted
much interest but has only limited direct experimental
support thus far (48), although microbes might still precip-
itate insulitis prematurely or cause it to convert more rap-
idly to diabetes.
Finally, it is important to explain why immunity, rather
than tolerance, issues from this priming process. A popular
paradigm has been that necrotic cells are immunogenic and
apoptotic cells tolerogenic. However, apoptotic cells can
also provoke an immune response under the appropriate
conditions, for example, when present in high enough
numbers, physiologically stressed, or exposed to inflamma-
tory cytokines such as TNF-  and IL-1  (45). In addition,
several studies have linked the presentation of autoantigens
and production of autoantibodies to apoptotic cells, notably
in systemic lupus erythematosus (49). An additional consid-
eration is that the response elicited from T cells by the pre-
sentation of antigens released from dying   cells in the
PLNs may not represent immunity in the strict sense. In
both NOD mice and TCR tg derivatives, in particular
BDC2.5, there can be a long lag between the initiation of
insulitis and the development of diabetes because the T cell
infiltrate remains “innocuous” or benign (50, 51). The ex-
planation for the T cells’ good behavior remains controver-
sial, being variously attributed to a TH2 phenotype (51),
IL-10 production (52), or other factors (53). Perhaps this
behavior represents a state of immune deviation, something
between true immunity and true tolerance, the result of
being primed by DCs loaded in the pancreas with apop-
totic   cell fragments. Another possibility is that regulatory
T cells also emanate from the priming process, akin to the
scenario invoked by Hugues et al. (28).T
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Curing type-I diabetes is an important objective; pre-
venting it is a goal of even greater import. Elucidating the
events that precipitate T cell invasion of the islets will pro-
vide the necessary framework for achieving this goal. Here,
we have identified one such critical event, an event that
probably takes place in all mouse strains, but is provocative
in NOD mice because of their autoreactive repertoire.
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